focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Regulatory News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,783.50
Bid: 1,780.00
Ask: 1,780.50
Change: -29.00 (-1.60%)
Spread: 0.50 (0.028%)
Open: 1,792.50
High: 1,802.00
Low: 1,775.50
Prev. Close: 1,812.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

29 Nov 2023 15:23

RNS Number : 1069V
GSK PLC
29 November 2023
 

TR-1: Standard form for notification of major holdings

1. Issuer Details

ISIN

GB00BN7SWP63

Issuer Name

GSK PLC

UK or Non-UK Issuer

UK

2. Reason for Notification

An acquisition or disposal of voting rights

3. Details of person subject to the notification obligation

Name

GSK plc

City of registered office (if applicable)

BRENTFORD

Country of registered office (if applicable)

United Kingdom

4. Details of the shareholder

Full name of shareholder(s) if different from the person(s) subject to the notification obligation, above

 

City of registered office (if applicable)

 

Country of registered office (if applicable)

 

5. Date on which the threshold was crossed or reached

23-Nov-2023

6. Date on which Issuer notified

23-Nov-2023

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8.A)

% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights held in issuer

Resulting situation on the date on which threshold was crossed or reached

4.812370

0.000000

4.812370

197068169

Position of previous notification (if applicable)

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached

8A. Voting rights attached to shares

Class/Type of shares ISIN code(if possible)

Number of direct voting rights (DTR5.1)

Number of indirect voting rights (DTR5.2.1)

% of direct voting rights (DTR5.1)

% of indirect voting rights (DTR5.2.1)

GB00BN7SWP63

197068169

4.812370

Sub Total 8.A

197068169

4.812370%

8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))

Type of financial instrument

Expiration date

Exercise/conversion period

Number of voting rights that may be acquired if the instrument is exercised/converted

% of voting rights

 

Sub Total 8.B1

8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))

Type of financial instrument

Expiration date

Exercise/conversion period

Physical or cash settlement

Number of voting rights

% of voting rights

 

Sub Total 8.B2

9. Information in relation to the person subject to the notification obligation

1. Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer.

Ultimate controlling person

Name of controlled undertaking

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

 

10. In case of proxy voting

Name of the proxy holder

 

The number and % of voting rights held

 

The date until which the voting rights will be held

 

11. Additional Information

The notification relates to the transfer at market value of 20.0 million treasury shares held by GSK plc to GSK plc's UK Employee Share Ownership Trust required to meet the expected requirement arising from awards made under GSK plc's Long Term Incentive Plan until 2026 vestings.Please note, the total amount of voting rights has been rounded to 6 decimal places therefore there is a possibility of a rounding error.

12. Date of Completion

29-Nov-2023

13. Place Of Completion

London

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
HOLPPGPAGUPWGCB
Date   Source Headline
1st Feb 20247:00 amRNSStatement: Zantac (ranitidine) litigation
31st Jan 20247:00 amRNSFinal Results
29th Jan 20247:05 amRNSEMA accepts Arexvy filing for adults 50-59 at risk
29th Jan 20247:00 amRNSEuropean Commission authorises Omjjara in the EU
19th Jan 20243:30 pmRNSDirector/PDMR Shareholding
18th Jan 20245:00 pmRNSHolding(s) in Company
17th Jan 20243:30 pmRNSDirector/PDMR Shareholding
17th Jan 20247:00 amRNSGSK completes sale of shares in Haleon plc
16th Jan 20244:40 pmRNSGSK announces intention to sell shares in Haleon
16th Jan 20243:30 pmRNSDirector/PDMR Shareholding
10th Jan 20247:00 amRNSNucala approved in China for use in severe asthma
9th Jan 20247:00 amRNSGSK enters agreement to acquire Aiolos Bio
2nd Jan 20243:00 pmRNSTotal Voting Rights
21st Dec 20233:30 pmRNSDirector/PDMR Shareholding
20th Dec 20234:44 pmRNSPublication of EMTN Suppl.Prospcts
18th Dec 20237:00 amRNSJemperli plus Zejula Trial Meets Endpoint
13th Dec 20233:30 pmRNSDirector/PDMR Shareholding
12th Dec 20237:00 amRNSJapan accepts Arexvy filing for at risk adults
11th Dec 20237:00 amRNSJemperli plus chemotherapy EU authorisation
4th Dec 20233:02 pmRNSGSK publishes provisional 2024 dividend dates
1st Dec 20233:00 pmRNSTotal Voting Rights
30th Nov 20239:00 amRNSBlock Listing Application
29th Nov 20233:23 pmRNSHolding(s) in Company
27th Nov 20237:00 amRNSGSK announces positive DREAMM-7 headline results
21st Nov 20233:30 pmRNSDirector/PDMR Shareholding
15th Nov 20233:00 pmRNSBlock listing Interim Review
13th Nov 20233:30 pmRNSDirector/PDMR Shareholding
13th Nov 20237:00 amRNSGSK receives positive CHMP opinion for momelotinib
1st Nov 20233:00 pmRNSTotal Voting Rights
1st Nov 20237:00 amRNS3rd Quarter Results
30th Oct 20237:00 amRNSJemperli trial meets overall survival endpoint
26th Oct 20237:00 amRNSNMPA approves Vocabria+Rekambys in China
25th Oct 20233:30 pmRNSDirector/PDMR Shareholding
25th Oct 20237:00 amRNSNew data for Arexvy, GSK’s RSV vaccine
20th Oct 20233:30 pmRNSDirector/PDMR Shareholding
18th Oct 20233:30 pmRNSDirector/PDMR Shareholding
17th Oct 20233:30 pmRNSDirector/PDMR Shareholding
16th Oct 20237:00 amRNSJemperli plus chemotherapy positive CHMP opinion
13th Oct 20233:30 pmRNSDirector/PDMR Shareholding
12th Oct 20233:30 pmRNSDirector/PDMR Shareholding
11th Oct 20237:00 amRNSZantac (ranitidine) litigation
10th Oct 202311:00 amRNSHolding(s) in Company
9th Oct 20237:00 amRNSGSK and Zhifei announce vaccine partnership
6th Oct 20237:00 amRNSGSK completes sale of shares in Haleon plc
5th Oct 20234:46 pmRNSGSK announces intention to sell shares in Haleon
2nd Oct 20233:00 pmRNSTotal Voting Rights
27th Sep 20233:00 pmRNSDirectorate Change
25th Sep 20237:00 amRNSGSK RSV vaccine for older adults approved in Japan
21st Sep 20233:30 pmRNSDirector/PDMR Shareholding
19th Sep 20237:00 amRNSApretude for PrEP receives EMA approval

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.